Chen, C., Yu, J., Lin, C., Chu, P., Liao, L., Tsai, W., Dai, Y., Ko, M., Lai, A. Y., Lin, C., Chen, W., Tung, Y., Chen, K., Weng, S., Chen, P., Tseng, Y., Hsu, K., Chang, F., Hsu, F., Lai, Y., Jian, S., Hsu, C., Chan, D. Z. H., Lin, Y., Lu, J., Cho, H., Wang, C., Lim, L., Kuo, T., Gao, Y., Wu, P., Liao, T., Wu, L., Chi, J., Huang, C., Hu, A., Yan, M., Wang, H., Huang, A. S. (2025). iPSC-derived, multiplex-engineered CD8αβT cells deliver antigen-specific, potent, and durable tumor cytotoxicity without CD4αβT support – powering scalable, off-the-shelf allogeneic αβT cell therapy in hematological malignancies. Blood. https://doi.org/10.1182/blood-2025-2327